Thomsen and Nordestgaard test the hypothesis that overweight and obesity with and without metabolic syndrome are associated with increased risk of myocardial infarction and ischemic heart disease. Jackson provides an Invited Commentary.
Smith et al compare the relative clinical cardiovascular safety of 2 commonly used oral estrogen drugs—conjugated equine estrogens and estradiol. Their case-control study compares cardiovascular event risk among 384 postmenopausal women aged 30 to 79 years using oral hormone therapy. Incident venous thrombosis was the primary clinical outcome.
To define trends in thyrotropin levels at the initiation of levothyroxine therapy and the risk of developing a suppressed thyrotropin level after treatment, Taylor et al performed a retrospective cohort study using data from the UK Clinical Practice Research Datalink. They assessed the odds of initiation of therapy at thyrotropin levels of 10.0 mIU/L or less.
Cohen et al determined whether a nurse-led or dietician-led cardiovascular risk factor education program would improve risk factor reduction over the long term after an acute coronary syndrome. Patients underwent an education program in a House of Education or were treated according to physicians’ standard of care. See the Invited Commentary by Fihn.
Than and coauthors compared the effectiveness of a rapid diagnostic pathway with a standard-care diagnostic pathway for the assessment of patients with possible cardiac chest pain in a usual clinical practice setting. See also the Invited Commentary by Rahko.
Joynt et al examine CEO compensation at private nonprofit hospitals and examine its relationship with quality metrics. Invited commentary provided by Browner.
Mason and coauthors determine if gabapentin increases rates of sustained abstinence and no heavy drinking and decreases alcohol-related insomnia, dysphoria, and craving, in a dose-dependent manner. See the Invited Commentary by Nunes.
Buchhalter and colleagues describe features and outcomes of patients who underwent cardiovascular implantable electronic device deactivation. Also see the Invited Commentary by Matlock and Mandrola.
To inform the debate about appropriate standards, Moore and Furberg studied the development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US FDA in 2008. Carpenter provides an Invited Commentary.
Rillamas-Sun and colleagues investigate whether higher baseline body mass index and waist circumference affect women’s survival to age 85 years without major chronic disease (coronary disease, stroke, cancer, diabetes mellitus, or hip fracture) and mobility disability.
Soliman and colleagues examine the risk of incident myocardial infarction (MI) associated with atrial fibrillation (AF). In a related editorial, Dukes and Marcus further explore the association between MI and AF.
Stout et al describe breast magnetic resonance imaging trends and indications in a community setting.
Wernli et al describe patterns of breast magnetic resonance imaging use in US community practice during the period 2005 through 2009.